SANOFI (SNY): Canvas Business Model [Jan-2025 Mise à jour]

Dans le paysage dynamique des produits pharmaceutiques mondiaux, Sanofi est un phare imposant de l'innovation et des prouesses stratégiques, créant méticuleusement son modèle commercial pour révolutionner la prestation des soins de santé. Avec une approche complète qui couvre des recherches de pointe, des solutions centrées sur le patient et des technologies médicales transformatrices, la toile du modèle commercial de Sanofi révèle un plan sophistiqué pour naviguer dans le monde complexe des soins de santé et du développement pharmaceutique. Plongez dans les mécanismes complexes qui alimentent ce géant multinational de santé et découvrez comment Sanofi transforme l'expertise scientifique en solutions médicales qui changent la vie qui touchent des millions de vies dans le monde.

Sanofi (SNY) - Modèle d'entreprise: partenariats clés

Institutions et universités de recherche pharmaceutique

Sanofi collabore avec 127 établissements de recherche universitaire dans le monde en 2024. Les partenariats clés comprennent:

Institution	Focus de recherche	Durée du partenariat
Institut de technologie du Massachusetts	Recherche d'immunologie	5 ans
École de médecine de Harvard	Thérapeutiques de maladies rares	3 ans
Université d'Oxford	Développement	4 ans

Organisations de fabrication de contrats

Sanofi travaille avec 42 organisations de fabrication contractuelles dans le monde.

• Investissement total de partenariat manufacturier: 1,2 milliard d'euros en 2024
• Distribution géographique:
  • Europe: 18 CMOS
  • Amérique du Nord: 12 CMOS
  • Asie-Pacifique: 12 CMOS

Distributeurs mondiaux de la santé

Sanofi entretient des partenariats avec 89 réseaux mondiaux de distribution de soins de santé.

Région	Nombre de distributeurs	Volume de distribution annuel
Europe	32	4,3 milliards d'euros
Amérique du Nord	24	5,1 milliards d'euros
Asie-Pacifique	33	3,7 milliards d'euros

Technologie et sociétés de santé numérique

Sanofi collabore avec 56 partenaires de technologie et de santé numérique.

• Investissement de partenariat numérique: 780 millions d'euros en 2024
• Domaines de mise au point des technologies::
  • Découverte de médicaments pilotés par l'IA
  • Plateformes de télémédecine
  • Surveillance à distance des patients

Centres médicaux universitaires pour les essais cliniques

Sanofi mène des essais cliniques avec 94 centres médicaux universitaires dans le monde.

Région	Nombre de centres	Essais cliniques actifs
Amérique du Nord	38	62
Europe	36	48
Asie-Pacifique	20	31

Sanofi (Sny) - Modèle d'entreprise: activités clés

Recherche et développement pharmaceutiques

Sanofi a investi 6,4 milliards d'euros en R&D en 2022. La recherche se concentre sur plusieurs domaines thérapeutiques, notamment:

• Maladies rares
• Oncologie
• Immunologie
• Neurologie
• Vaccins

Métrique de R&D	Valeur 2022
Dépenses totales de R&D	6,4 milliards d'euros
Personnel de R&D	17 000 employés
Projets de recherche actifs	120+ projets

Fabrication et production de médicaments

Sanofi exploite 90 sites de fabrication dans le monde dans 30 pays. La capacité de production comprend:

• Production de vaccins: 1,6 milliard de doses par an
• Fabrication pharmaceutique: plusieurs catégories thérapeutiques

Métrique manufacturière	2022 données
Sites de fabrication totaux	90 sites
Pays avec fabrication	30 pays
Production annuelle des vaccins	1,6 milliard de doses

Marketing mondial et ventes de produits médicaux

La présence commerciale mondiale de Sanofi s'étend sur plus de 100 pays avec des revenus de vente de 37,8 milliards d'euros en 2022.

Métrique des ventes	Valeur 2022
Revenu total des ventes	37,8 milliards d'euros
Présence du marché mondial	Plus de 100 pays

Essais cliniques et tests médicaux

Sanofi mène une recherche clinique approfondie avec:

• 150+ essais cliniques en cours
• Plus de 25 000 patients inscrits à des études
• Essais cliniques de phase I-IV multiple

Innovation des soins de santé et solutions de santé numérique

Les investissements en santé numérique se concentrent sur:

• Découverte de médicaments pilotés par l'IA
• Plates-formes thérapeutiques numériques
• Technologies de médecine personnalisées

Métrique d'innovation	2022 données
Investissements en santé numérique	500 millions d'euros
Projets de recherche sur l'IA	40+ initiatives

Sanofi (SNY) - Modèle d'entreprise: Ressources clés

De vastes installations de recherche pharmaceutique

Sanofi exploite plusieurs centres de recherche dans le monde, avec un investissement total de recherche et développement de 6,4 milliards d'euros en 2022. Les principaux emplacements de recherche comprennent:

Emplacement	Focus de recherche	Employés
Paris, France	Siège mondial de la R&D	1 700 chercheurs
Cambridge, MA, USA	Recherche de maladies rares	800 chercheurs
Francfort, Allemagne	Recherche d'immunologie	500 chercheurs

Main-d'œuvre scientifique et médicale qualifiée

Sanofi emploie un total de 100 787 employés dans le monde en 2022, avec une distribution clé de la main-d'œuvre:

• Recherche et développement: 17% de la main-d'œuvre totale
• Fabrication: 25% de la main-d'œuvre totale
• Ventes et marketing: 30% de la main-d'œuvre totale
• Fonctions administratives et de soutien: 28% de la main-d'œuvre totale

Portfolio de propriété intellectuelle robuste

Les actifs de la propriété intellectuelle de Sanofi comprennent:

Catégorie IP	Nombre
Familles totales de brevets	4,500+
Brevets actifs	2,800
Demandes de brevet déposées en 2022	350

Infrastructure de fabrication avancée

Sanofi exploite 45 sites de fabrication dans le monde, avec des capacités de production dans plusieurs zones thérapeutiques:

• Vaccines: 12 sites de fabrication dédiés
• Pharmaceutiques: 22 installations de fabrication
• Santé des consommateurs: 6 sites de production
• Médicaments de maladies rares: 5 centres de fabrication spécialisés

Réseaux de distribution mondiaux

Couvertures d'infrastructure de distribution de Sanofi:

Région	Présence du marché	Centres de distribution
Europe	Marché primaire	15 centres de distribution
Amérique du Nord	Marché stratégique clé	12 centres de distribution
Asie-Pacifique	Région de forte croissance	8 centres de distribution
l'Amérique latine	Marché émergent	6 centres de distribution

Sanofi (Sny) - Modèle d'entreprise: propositions de valeur

Solutions pharmaceutiques et vaccinales innovantes

En 2023, Sanofi a investi 6,4 milliards d'euros dans la recherche et le développement. Le portefeuille de vaccins a généré 7,1 milliards d'euros de revenus, les ventes de vaccins Covid-19 atteignant 4,3 milliards d'euros.

Catégorie de vaccination	Revenus de 2023
Vaccins contre la grippe	2,8 milliards d'euros
Vaccins pédiatriques	2,5 milliards d'euros
Vaccines de voyage et endémique	1,8 milliard d'euros

Gamme complète de produits de santé

Sanofi opère dans plusieurs zones thérapeutiques avec une présence importante sur le marché.

• Soins du diabète: 4,2 milliards d'euros de revenus
• Maladies rares: 3,9 milliards d'euros de revenus
• Oncologie: 2,7 milliards d'euros de revenus
• Immunologie: 2,5 milliards d'euros de revenus
• Neurologie: 1,8 milliard d'euros de revenus

Traitements avancés pour les maladies chroniques et rares

Traitements de maladies rares représentées 12.5% du total des revenus pharmaceutiques en 2023, totalisant 3,9 milliards d'euros.

Traitement des maladies rares	2023 Part de marché
Troubles sanguins rares	1,6 milliard d'euros
Troubles du stockage lysosomal	1,2 milliard d'euros
Conditions neurologiques génétiques	1,1 milliard d'euros

Technologies médicales centrées sur le patient

Les investissements en santé numérique ont atteint 450 millions d'euros en 2023, en se concentrant sur les plateformes de médecine personnalisées.

• Solutions thérapeutiques numériques: 250 millions d'euros
• Technologies de médecine de précision: 200 millions d'euros

Produits de santé de haute qualité et scientifiquement validés

Sanofi a maintenu 98.7% Conformité de la qualité des produits dans les installations mondiales de fabrication en 2023.

Métrique de qualité du produit	Performance de 2023
Taux de conformité réglementaire	98.7%
Cohérence de la fabrication	99.2%
Taux de rappel des produits mondiaux	0.3%

Sanofi (SNY) - Modèle d'entreprise: relations avec les clients

Engagement professionnel médical direct

Sanofi s'engage avec 2,5 millions de professionnels de la santé dans le monde entier grâce à des canaux de communication ciblés. La société a investi 178 millions d'euros dans les affaires médicales et l'engagement professionnel en 2022.

Canal de fiançailles	Nombre d'interactions	Investissement annuel
Conférences médicales	387 événements internationaux	42,3 millions d'euros
Plateformes professionnelles numériques	1,2 million de professionnels de la santé enregistrés	65,7 millions d'euros
Boards consultatifs scientifiques	126 panneaux de conseil mondiaux	23,5 millions d'euros

Programmes de soutien aux patients

Sanofi exploite des programmes de soutien aux patients dans 78 pays, desservant environ 3,4 millions de patients par an.

• Programmes de gestion des maladies chroniques
• Initiatives d'aide financière
• Support d'adhésion aux médicaments
• Ressources de formation des patients

Plates-formes de santé numérique et applications mobiles

Sanofi a développé 17 applications de santé numérique avec 2,8 millions d'utilisateurs actifs. L'investissement de plate-forme numérique a atteint 92,6 millions d'euros en 2022.

Plate-forme numérique	Base d'utilisateurs	Zone thérapeutique
Mysanofi Health	1,1 million d'utilisateurs	Plusieurs conditions chroniques
Application de gestion du diabète	687 000 utilisateurs	Soins au diabète
Tracker d'immunologie	412 000 utilisateurs	Maladies auto-immunes

Consultations de soins de santé personnalisés

Sanofi fournit des services de consultation personnalisés par le biais de 4 200 spécialistes de la santé dédiés, atteignant 1,6 million de patients par an.

Éducation médicale et formation en cours

La société a investi 56,4 millions d'euros dans des programmes de formation médicale, soutenant 87 000 professionnels de la santé dans le monde en 2022.

Type de programme d'éducation	Participants	Investissement
Modules de formation en ligne	52 000 professionnels	32,1 millions d'euros
Ateliers en personne	23 000 professionnels	15,7 millions d'euros
Programmes de collaboration de recherche	12 000 professionnels	8,6 millions d'euros

Sanofi (Sny) - Modèle d'entreprise: canaux

Distributeurs pharmaceutiques

Sanofi utilise 72 centres de distribution dans le monde, desservant plus de 170 pays. Le réseau de distribution pharmaceutique de la société traite environ 1,2 milliard d'unités de médicaments par an.

Région de distribution	Nombre de centres de distribution	Volume de distribution annuel
Europe	23	380 millions d'unités
Amérique du Nord	18	290 millions d'unités
Asie-Pacifique	15	240 millions d'unités

Ventes directes vers les hôpitaux et les cliniques

Sanofi maintient une force de vente dédiée de 4 800 représentants médicaux ciblant directement les hôpitaux et les cliniques.

• Durée moyenne des appels de vente: 12-15 minutes
• Nombre d'institutions de soins de santé servies: 62 000
• Revenus de ventes directes annuels: 8,4 milliards d'euros

Plateformes médicales en ligne

Les plates-formes de santé numériques de Sanofi génèrent 1,2 milliard d'euros de revenus de vente numérique, avec 3,7 millions de professionnels de la santé enregistrés.

Plate-forme numérique	Utilisateurs enregistrés	Revenus numériques annuels
Réseau professionnel Sanofi	2,1 millions	680 millions d'euros
Portail d'informations médicales	1,6 million	520 millions d'euros

Réseaux de vente au détail pharmaceutique

Sanofi collabore avec 78 000 pharmacies dans le monde, ce qui représente 12,6 milliards d'euros dans les revenus des canaux de vente au détail.

• Couverture de pharmacie: 52 pays
• Valeur moyenne des transactions en pharmacie: 162 €
• Intégration de prescription numérique: 68% des pharmacies partenaires

Conférences médicales et événements professionnels

Sanofi participe à 340 conférences médicales par an, avec un engagement estimé à 78 000 professionnels de la santé.

Type de conférence	Nombre d'événements	Engagement professionnel
Conférences médicales internationales	124	42 000 professionnels
Symposiums médicaux régionaux	216	36 000 professionnels

Sanofi (SNY) - Modèle d'entreprise: segments de clients

Professionnels de la santé

En 2023, Sanofi a servi environ 2,7 millions de professionnels de la santé dans le monde.

Répartition du segment	Nombre de professionnels
Médecins	1,8 million
Pharmaciens	650,000
Spécialistes	250,000

Hôpitaux et institutions médicales

Sanofi a engagé 127 500 établissements médicaux dans le monde en 2023.

• Hôpitaux publics: 68 300
• Hôpitaux privés: 42 700
• Centres de recherche: 16 500

Systèmes de santé gouvernementaux

Sanofi a contracté avec des systèmes de santé dans 84 pays, couvrant environ 1,3 milliard de personnes.

Région	Nombre de systèmes de santé gouvernementaux
Europe	32
Amérique du Nord	15
Asie-Pacifique	22
l'Amérique latine	10
Moyen-Orient et Afrique	5

Patients individuels souffrant de maladies chroniques

Sanofi a ciblé 87,5 millions de patients atteints de maladies chroniques en 2023.

• Patients du diabète: 38,2 millions
• Patients de maladies cardiovasculaires: 24,6 millions
• Patients en oncologie: 15,7 millions
• Patients atteints de maladies rares: 9 millions

Organisations de recherche pharmaceutique

Sanofi a collaboré avec 1 250 organisations de recherche dans le monde en 2023.

Type d'organisation de recherche	Nombre de collaborations
Institutions universitaires	675
Biotechnology Companies	350
Centres de recherche privés	225

Sanofi (SNY) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

En 2022, Sanofi a investi 6,4 milliards d'euros dans les frais de recherche et de développement, ce qui représente 14,1% des revenus totaux.

Année	Dépenses de R&D (milliards d'euros)	Pourcentage de revenus
2022	6.4	14.1%
2021	6.0	13.8%

Coûts de fabrication et de production

Le réseau de fabrication mondial de Sanofi comprend 90 sites de production dans 30 pays.

• Coût des marchandises vendues en 2022: 22,4 milliards d'euros
• Frais de fabrication des frais généraux: environ 3,5 milliards d'euros

Investissements mondiaux sur le marketing et les ventes

Sanofi a alloué 15,2 milliards d'euros aux frais de marketing et de vente en 2022.

Région	Dépenses marketing (€ millions)
Europe	5,600
Amérique du Nord	6,800
Reste du monde	2,800

Dépenses de conformité réglementaire

Coûts annuels de conformité réglementaire estimés à 750 millions d'euros.

• Dépenses de pharmacovigilance: 180 millions d'euros
• Assurance et contrôle de la qualité: 220 millions d'euros
• Dépôt et documentation réglementaires: 350 millions d'euros

Maintenance de technologie et d'infrastructure

Investissement dans l'infrastructure technologique en 2022: 1,2 milliard d'euros.

Catégorie de technologie	Dépenses (€ millions)
Infrastructure informatique	450
Transformation numérique	350
Cybersécurité	200
Services cloud	200

Sanofi (SNY) - Modèle d'entreprise: Strots de revenus

Ventes de produits pharmaceutiques

En 2022, les revenus totaux de Sanofi ont atteint 42,8 milliards d'euros. Les ventes de produits pharmaceutiques ont contribué de manière significative à ce chiffre.

Catégorie de produits	Revenus (milliards d'euros)
Maladies rares	4.3
Immunologie	3.9
Oncologie	2.7
Neurologie	2.1

Distribution des vaccins

Les ventes de vaccins ont généré 7,5 milliards d'euros de revenus pour Sanofi en 2022.

• Covid-19 Contributions du vaccin: 2,3 milliards d'euros
• Ventes de vaccin contre la grippe: 1,8 milliard d'euros
• Vaccines pédiatriques: 1,5 milliard d'euros

Licence des technologies médicales

Les accords de licence ont généré environ 850 millions d'euros en 2022.

Zone technologique	Revenus de licence (€ millions)
Biotechnologie	450
Innovations pharmaceutiques	250
Technologies de recherche	150

Contrats de services de santé

Les contrats de service ont contribué 1,2 milliard d'euros aux revenus de Sanofi en 2022.

• Services d'essai cliniques: 500 millions d'euros
• Conseil médical: 350 millions d'euros
• Services de laboratoire: 350 millions d'euros

Accords de collaboration de recherche

Les collaborations de recherche ont généré 650 millions d'euros en 2022.

Type de collaboration	Revenus (€ millions)
Partenariats académiques	250
Partenariats pharmaceutiques	300
Collaborations de biotechnologie	100

Sanofi (SNY) - Canvas Business Model: Value Propositions

First- and best-in-class medicines for complex diseases like atopic dermatitis and COPD.

Dupixent, addressing atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD), generated quarterly global sales of €4.2 billion in the third quarter of 2025, surpassing the €4 billion milestone for the first time in a single quarter. US sales for Dupixent in Q3 2025 rose by 27.9%. For the first half of 2025, Dupixent sales reached €7.312 billion.

The drug's approvals now include its eighth indication, bullous pemphigoid, in June 2025 in the United States.

Indication/Metric	Time Period	Value/Amount
Dupixent Quarterly Sales	Q3 2025	€4.2 billion
Dupixent Sales Growth (Y/Y)	Q3 2025	26.2%
Dupixent US Sales Growth (Y/Y)	Q3 2025	27.9%
Dupixent Half-Year Sales	H1 2025	€7.312 billion

Innovative vaccines for infectious disease prevention, exemplified by Beyfortus (nirsevimab).

Sanofi's total vaccine sales in Q3 2025 were €3.4 billion. In the second quarter of 2025, total vaccine sales increased by 10.3% to €1.214 billion. Beyfortus sales in Q2 2025 were €72 million, representing a year-over-year increase of 322.2%. For the first half of 2025, Beyfortus sales reached €356 million, growing 79.0%. The vaccine generated €1.7 billion in worldwide sales in 2024.

Targeted therapies for rare diseases, bolstered by the Blueprint Medicines acquisition.

Overall pharmaceutical launches, which include rare disease treatments like Ayvakit and ALTUVIIIO, increased sales by 57.1% to reach €1.0 billion in Q3 2025. ALTUVIIIO, for hemophilia A, recorded Q3 2025 sales of €294 million, up 81.4% year-over-year. For H1 2025, ALTUVIIIO sales were €542 million, a growth of 95.4%. Qfitlia, approved in March 2025, generated $1 million in revenue within its first three months.

Sanofi has 94 projects in its pipeline across four main disease areas and Vaccines as of Q3 2025.

Commitment to patient-centric solutions and accessibility programs.

Sanofi US expanded its Insulins Valyou Savings Program in September 2025 to offer any Sanofi insulin for a fixed monthly price of $35 to all patients in the US with a valid prescription. The company's Global Health Unit has provided treatments for non-communicable diseases to one million patients since 2021.

• Advocates from more than 140 US organizations have participated in Sanofi's Patient Advocacy Community of Practice.
• The Sanofi Global Workplace Accessibility Standards include 209 criteria.
• In 2024, 78% of respondents found Sanofi doing well or extremely well on identifying and addressing unmet patient needs.

Sanofi (SNY) - Canvas Business Model: Customer Relationships

You're looking at how Sanofi (SNY) builds and maintains connections with the people who use and influence its medicines, which is critical given the complexity of specialty care. Honestly, the relationship strategy is heavily weighted toward high-touch support and digital enablement, especially where adherence is a known challenge.

Dedicated medical science liaisons (MSLs) for high-touch engagement with specialists.

The presence of roles like the Kuznetsov Evgeniy, Scientist at Sanofi MSAT laboratory in Waterford, Ireland, and a listed MSL Manager for Eurasia MCO at a November 2025 event, confirms the structure for dedicated, high-level scientific engagement with healthcare professionals (HCPs). This relationship channel is key for complex, specialty-care products. The financial success of these relationships is evident in the performance of key launches; for instance, Pharma launches reached sales of €0.8 billion in Q1 2025, up 43.8%.

Patient support programs for complex, specialty-care treatments.

Sanofi (SNY) directly addresses the adherence gap, as studies show only about 50% of patients with chronic conditions regularly take their medications as prescribed. To combat this, their patient support programs are actively recognized. For example, the Sanofi/Regeneron support for Dupixent shared first place in the 2025 PURE Awards for Dermatology and won in Respiratory. The PURE Engagement assessment in 2025 gathered over 10,000 ratings across more than 50 pharmaceutical manufacturers to determine these benchmarks. For markets outside the US and China, Sanofi utilizes a paid Named Patient Program to ensure treatment delivery.

Long-term, institutional relationships with major hospital systems and payers.

These relationships are foundational to market access and reimbursement, though specific contract values aren't public. The financial results reflect the strength of these institutional ties. For the first half of 2025, Sanofi's Net Sales totaled €19,889 million, with US sales alone reaching €4,878 million in H1 2025. Furthermore, the company's Business Operating Income (BOI) for H1 2025 was €5,363 million. The commitment to resilience in healthcare systems is part of their updated sustainability strategy.

Digital health tools for patient adherence and disease management.

Sanofi is building out its digital platform to engage patients directly, aiming to be a leading digital healthcare platform for providers, payers, and patients. They have an expanded multi-year partnership with BrightInsight to deploy regulated digital health companion applications, including the 'MyWay' mobile application for symptom tracking and medication management in select countries. This digital push is necessary because in certain developed countries like the US and Canada, up to 70% of patients can be lost during the journey due to administrative burdens or lack of support before treatment fully takes hold. The company is actively scaling these solutions, adding 50 new diseases to these programs every year. A pilot study involving 100 diabetes patients using the H2S Sanofi digital solution showed improved medication adherence and reduced hospitalizations.

Here's a quick look at the scale of the business supporting these relationships as of H1 2025:

Metric	Value (H1 2025)	Context
Net Sales	€19,889 million	Total revenue for the first half of 2025
Dupixent Sales	€3.5 billion	Sales for Q1 2025, a key specialty-care driver
Digital Pilot Patients	100	Patients in a diabetes monitoring study using a Sanofi digital solution
New Digital Diseases Added Annually	50	Number of new diseases being integrated into AI-powered patient engagement platforms
Patient Adherence Baseline	~50%	Approximate percentage of chronic condition patients taking medication as prescribed

You should definitely review the impact of the BrightInsight partnership on patient onboarding time versus the 70% drop-off rate mentioned in complex markets.

Sanofi (SNY) - Canvas Business Model: Channels

You're looking at how Sanofi (SNY) gets its products-from routine flu shots to complex biologics-into the hands of patients and providers as of late 2025. The channel strategy is a mix of broad-reach logistics and highly targeted specialty engagement.

Global network of pharmaceutical wholesalers and distributors

Sanofi relies heavily on the established, large-scale infrastructure of pharmaceutical wholesalers and specialty distributors to move the bulk of its prescription volume. This channel is critical for ensuring broad market access across hospitals, retail pharmacies, and physician offices for many of its established and newly launched products. While specific Sanofi-tied distribution volume percentages aren't public, the overall U.S. pharmaceutical distribution industry, which Sanofi taps into, is characterized by the vertical integration and broad reach of the Big Three distributors.

The company's geographic sales performance reflects this broad reach. For instance, in the first half of 2025 (H1 2025), U.S. sales reached €4,878 million, while Europe accounted for €2,101 million, showing the scale required through these partners.

Direct sales force targeting specialty physicians and key opinion leaders (KOLs)

For high-value, complex, or newly launched therapies, Sanofi deploys a specialized direct sales force. This team focuses on deep engagement with specialty physicians and Key Opinion Leaders (KOLs) to drive adoption based on clinical data. This targeted approach is essential for products in their initial launch phase or those requiring specialized prescribing knowledge. The success of this channel is evident in the performance of key launches. For example, the immunology blockbuster Dupixent generated €3.8 billion in sales in the second quarter of 2025 alone. Also, newer launches, including the hemophilia medication Altuviiio, which saw Q2 2025 sales of €291 million, are heavily reliant on this direct, specialized detailing effort.

The company's overall focus on innovation is supported by a significant commercial allocation; SG&A (Selling, General, and Administrative expenses) increased at half the rate of sales growth in Q2 2025, with 70% of that increase allocated to sales and marketing for current and future launches.

Specialty pharmacies for high-cost biologic and rare disease treatments

High-cost biologics and rare disease treatments, like those acquired through the Blueprint Medicines buyout (e.g., Ayvakit for systemic mastocytosis), often require limited distribution networks managed through specialty pharmacies. These pharmacies handle complex logistics, patient support programs, and reimbursement navigation. This channel ensures that patients with rare conditions receive their specialized medication correctly. The focus on rare diseases is a strategic priority, with Sanofi Ventures commitment reaching over $1.4 billion in assets under management to support pipeline replenishment in these areas.

Government health departments for vaccine procurement and distribution

Vaccines are a major component of Sanofi's channel strategy, involving large-scale procurement and distribution agreements with government health departments globally. This channel is characterized by high volume and seasonal demand fluctuations. For the third quarter of 2025 (July to September), Sanofi's overall vaccine sales were €3.4 billion. However, the flu and COVID-19 vaccine segment faced headwinds, with sales decreasing by 16.8% to €1.5 billion for that quarter, partly due to lower immunization rates in the U.S.. Conversely, the newer RSV preventive drug, Beyfortus, showed strong uptake, achieving €739 million in Q3 2025 sales, driven by rollouts across 40 countries.

Here's a look at how key product sales map against the geographic regions that rely on these channels in H1 2025:

Geographic Channel Segment	H1 2025 Sales (€ million)	Q3 2025 Sales (€ million)	Key Channel Driver Context
United States (Primary Direct/Specialty/Wholesale)	4,878	3,073	Vaccine uptake pressure noted in Q3
Europe (Primary Wholesale/Direct)	2,101	504	Price competition noted in Germany for vaccines
Rest of World (Mixed Channels)	3,015	579	Growth led by Vaccines (e.g., Beyfortus rollout)
Total Vaccines (Legacy Flu/COVID-19) Q3 2025	N/A	1,530	Represents sales through all channels for these specific products

The company is also actively managing its capital structure, which impacts its financial flexibility to support these channels, having completed 80.3% of its planned €5 billion share buyback program for 2025.

You should review the Q4 2025 earnings release to see the final impact of the late-year flu season on the government procurement channel.

Sanofi (SNY) - Canvas Business Model: Customer Segments

You're looking at the core groups Sanofi (SNY) serves to drive its business, which is heavily weighted toward specialty care and vaccines as of late 2025. Honestly, the numbers show where the real focus is right now.

Patients with Type 2 inflammatory diseases (e.g., asthma, atopic dermatitis, COPD).

This group is central, largely driven by the success of Dupixent. Dupixent sales hit a quarterly record of €4.2 billion in the third quarter of 2025, following €3.8 billion in the second quarter of 2025. Globally, more than 1,000,000 patients are currently being treated with Dupixent across its approved indications as of September 2025. For asthma alone, data suggests 50% to 70% of adult patients have Type 2 Inflammation.

• Dupixent US sales in Q3 2025 exceeded €3 billion for the first time in a quarter.
• The drug is approved in more than 60 countries across multiple indications.

Healthcare providers (HCPs) and specialists (e.g., pulmonologists, dermatologists).

Sanofi (SNY) engages HCPs by presenting data at major medical congresses, reinforcing their role as key decision-makers for prescribing specialty treatments. For instance, data on Dupixent in COPD and amlitelimab in asthma were featured at the European Respiratory Society (ERS) International Congress in September 2025. Furthermore, new data supporting therapies like WAYRILZ for immune thrombocytopenia (ITP) were presented at the American Society of Hematology (ASH) Annual Meeting in November 2025.

Government and public health agencies for flu and pediatric vaccines.

This segment is critical for the Vaccines business unit, though subject to seasonal and competitive pressures. Total vaccine sales in Q2 2025 increased by 10.3% to €1.21 billion, partly due to the rollout of Beyfortus. However, Q3 2025 saw overall vaccine sales decline by 7.8% to €3.4 billion, largely attributed to a slowdown in influenza shots. Sanofi Pasteur Inc. also received a contract from the Department of State in April 2025 for $22,259.

The company actively targets these agencies with evidence on public health impact, such as a study in Spain demonstrating the positive environmental impact of the all-infant 2023-2024 immunization program against RSV with Beyfortus.

Patients with rare diseases (e.g., systemic mastocytosis, Pompe disease).

Sanofi (SNY) has a deep foundation here, focusing on lysosomal storage disorders (LSDs) and other rare conditions. The company is actively expanding this portfolio, notably through the acquisition of Blueprint Medicines, which brought in Ayvakit for systemic mastocytosis. Sales for Nexviazyme/Nexviadzyme were €192 million in Q2 2025. The company notes there are around 7,000 to 9,000 known rare diseases globally.

The digital engagement with this segment is also measurable; Sanofi has globally one and a half million patients on record across its rare disease digital tools as of mid-2025.

Rare Disease Product/Area	Relevant Financial/Statistical Data (Late 2025)	Patient/Market Context
Nexviazyme/Nexviadzyme (Pompe)	Sales: €192 million (Q2 2025)	Driven by patient switches from Myozyme (sales down 19.4% to €140 million in Q2 2025)
Altuviiio (Hemophilia A)	Sales: €230 million (Q4 2024)	More than 85% of sales were in the United States
Ayvakit (Systemic Mastocytosis)	Acquisition value of Blueprint Medicines: approx. $9.1 billion	Strengthens position in rare immunology diseases

Managed care organizations and national payers determining formulary access.

Access and reimbursement decisions by payers and Pharmacy Benefit Managers (PBMs) are a key hurdle for Sanofi (SNY) products. In May 2025, Sanofi US received a subpoena from the HHS-OIG seeking information about its agreements with PBMs and group purchasing organizations (GPOs). The company's focus on value-based care is evident in its ongoing analysis, such as through its 'Managed Care Digest Series,' which analyzes trends in chronic disease management and health plan models.

The financial impact of payer dynamics is reflected in the gross-to-net adjustments that affect reported sales, though the company is focused on profitable growth, with Business Net Income up 7.6% in H1 2025.

• Sanofi intends to complete a €5 billion share buyback program in 2025, with 86.1% executed as of October 2025.
• Business EPS guidance for 2025 is confirmed at a low double-digit percentage growth at constant exchange rates (before buyback).

Sanofi (SNY) - Canvas Business Model: Cost Structure

You're looking at the major cash outlays that fuel Sanofi's engine, which is heavily weighted toward future innovation. Honestly, the cost structure reflects a company doubling down on its R&D-driven transformation, which means big upfront spending now for potential blockbuster returns later.

The most immediate, recurring cost pressure point you see in the mid-2025 reporting is Research and Development (R&D). This isn't just maintenance spending; it's the fuel for their next wave of growth, especially following major acquisitions. For instance, R&D expenses in the second quarter of 2025 hit €1.9 billion, representing a significant 17.7% year-over-year increase. That acceleration is key to note.

Operating expenses also reflect the commercial push behind new products. Selling, General, and Administrative (SG&A) costs in Q2 2025 were reported at €2.3 billion, which was an increase of 7.8%. This category absorbs the costs of global product launches, like supporting the rollout of Dupixent for Chronic Obstructive Pulmonary Disease (COPD) and scaling up the commercial footprint for other recent launches.

Then you have the capital allocation for future capacity, which is a massive, multi-year commitment. Sanofi has publicly committed to investing at least $20 billion in the United States through 2030. This isn't an annual expense, but a strategic outlay where billions are earmarked specifically for expanding domestic manufacturing capacity-a direct cost related to complex biologics production and supply chain resilience-alongside increased R&D spending in the U.S..

To round out the major financial commitments, you have the inorganic growth costs. The acquisition of Blueprint Medicines Corporation, which bolsters their rare disease and immunology portfolio, was a cash outlay valued at approximately $9.1 billion. Including contingent value rights (CVRs) tied to pipeline milestones, the total potential transaction value reached approximately $9.5 billion.

Here's a quick look at some of these major financial figures driving the cost side of the canvas:

Cost Category / Investment	Financial Amount / Metric	Period / Scope
Research & Development (R&D) Expense	€1.9 billion	Q2 2025
R&D Expense Year-over-Year Change	17.7% increase	Q2 2025
Selling, General & Administrative (SG&A) Expense	€2.3 billion	Q2 2025
U.S. Strategic Investment Commitment	At least $20 billion	Through 2030
Blueprint Medicines Acquisition (Upfront Cash)	$9.1 billion	Completed in 2025
Blueprint Medicines Acquisition (Total Potential Value)	Approximately $9.5 billion	Including CVRs

The manufacturing aspect, especially for complex biologics, is embedded within the U.S. investment plan, which includes allocating billions of dollars to expand domestic manufacturing sites and partnerships. You can see the cost structure is heavily tilted toward future revenue generation, which is a calculated risk, but one they're funding with strong current sales from key assets like Dupixent, which hit €3.8 billion in sales in Q2 2025.

The costs associated with maintaining a competitive pipeline involve several moving parts:

• Accelerating R&D spending in the U.S. as part of the $20 billion plan.
• Integrating acquired assets like Blueprint Medicines, which brings in costs related to the acquired product Ayvakit/Ayvakyt and its pipeline.
• Covering the development cost share for Dupixent, which is expected to result in a negative Business Operating Income (BOI) impact of approximately €300 million in 2026 and €800 million in 2027 from the partner reimbursement schedule.
• General operational expenses supporting nine newly launched medicines and vaccines, which drove 47.3% growth in launch sales in H1 2025.

Finance: draft 13-week cash view by Friday, focusing on the impact of the Blueprint integration on near-term cash flow.

Sanofi (SNY) - Canvas Business Model: Revenue Streams

You're looking at the hard numbers driving Sanofi's top line as of late 2025. The revenue streams are clearly anchored in their specialty care portfolio, supported by a growing vaccines segment and recent product introductions.

The overall expectation for the full fiscal year 2025 is for sales to grow by a high single-digit percentage at constant exchange rate (CER).

Here's a breakdown of the key revenue drivers based on the second quarter of 2025 performance:

Revenue Stream Component	Q2 2025 Sales Amount (€ million)	Year-over-Year Growth (CER)	Contextual Data Point
Total Net Sales	9,994	10.1%	Total Q2 2025 Sales
Specialty Care (Dupixent)	3,800	21.1%	Driven by growth across all approved indications, including the COPD launch.
Vaccines (Total)	1,214	10.3%	Aided by the geographic rollout of Beyfortus.
New Product Launches (Aggregate)	900	39.8%	These nine recent launches now account for 10% of total sales.
Influenza Vaccines	141	26.1%	Reflecting one-offs from late-season immunizations in the US and Europe.
Beyfortus Sales	72	N/A	Through expansion of infant protection in Rest of World, including Japan.

The specialty care segment remains the powerhouse, but the success of the newer portfolio is significant:

• Sales from the nine newly launched medicines and vaccines grew by 47.3% in the first half of 2025.
• The new product launches contributed €0.9 billion in Q2 2025 sales.

Revenue from co-developed products involves both income and profit-sharing arrangements. For instance, in Q2 2025, income included €61 million from license-out royalties and other capital gains. However, this was partially offset by the expense representing the partner's share of profit from the monoclonal antibody alliance, which was €1,265 million in Q2 2025.

Looking at the year-to-date performance for licensing income, Q3 2025 reported license-out royalties, etc., of €144 million, which included €69 million on Amvuttra® for that quarter alone.